Compugen Q2 2025 Earnings Report

Compugen EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.07
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Compugen Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.95 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Compugen Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 6, 2025
• Conference Call Time: 12:30PM ET

Compugen (NASDAQ:CGEN) is a clinical-stage therapeutic discovery company that specializes in computational biology and predictive discovery for immuno-oncology. Leveraging proprietary in silico platforms, Compugen identifies novel targets and biomarkers to advance its pipeline of therapeutic and diagnostic candidates. The company’s core expertise lies in the intersection of computational genomics, bioinformatics and translational medicine to accelerate the identification and validation of immune-modulating targets and companion diagnostics.

Founded in 1983 and headquartered in Holon, Israel, Compugen has evolved from a bioinformatics services provider into a fully integrated discovery and development organization. Over the years, the company has forged collaborations with global pharmaceutical and biotech partners, including major alliances to advance its lead product candidates. Compugen’s pipeline encompasses multiple checkpoint pathway targets and translational diagnostic programs, with several late-stage clinical assets aimed at addressing solid tumors and hematological malignancies.

Compugen serves a global customer base and maintains research facilities in Israel and the United States, as well as strategic offices in New York. The company’s commercial efforts are complemented by its proprietary platforms—Predictive Target Discovery and Predictive Biomarker Discovery—that support both in-house development and collaborative projects. Through these platforms, Compugen has generated a robust portfolio of immuno-oncology discoveries and companion diagnostic candidates that aim to enhance the precision and efficacy of cancer therapies.

The company is governed by an experienced management team and board of directors, led by its President and Chief Executive Officer, who brings more than two decades of biopharmaceutical leadership. Under this leadership, Compugen continues to expand its discovery engine, advance its clinical programs and pursue strategic partnerships to bring novel immuno-oncology solutions to patients worldwide.